Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

Oregon Becomes the First State to Legalize Psilocybin for Therapy

Nov 4 • 3 min read

Last night (Nov. 3), voters overwhelmingly called for Oregon to become the first state in the nation to allow the use of psilocybin, the active ingredient in psychedelic mushrooms, in therapy. The vote mandates that the Oregon Health Authority (OHA) will establish a psilocybin-assisted therapy program for adults 21 and older over the next two…

MindMed Raises C$28.75M, Here’s What It’s For…

Nov 3 • 3 min read

On October 30, 2020, Mind Medicine (MMED) closed its previously announced financing, raising C$28.75M (USD $21.74M). The raise was an upsized round from the initial prospectus of C$25,000,500. The company raised the money from institutional investors by issuing 27,381,500 units at a price per unit of $1.05. As we have previously discussed, the unit consisted…

What’s The Real Value of ATAI Life Sciences?

Oct 30 • 7 min read

It’s no secret amongst psychedelic investors that ATAI Life Sciences has built up an impressive portfolio of companies. Backed by household names such as Peter Thiel, Mike Novogratz, and Steve Jurvetson, investors have been scrambling to be a part of the nearly $200 million raised to date. When and where the company will list is…

ATAI Life Sciences Has Massively Oversubscribed Series C

Oct 28 • 2 min read

Investors in the psychedelics industry have been scrambling the past couple of weeks to gain access to ATAI Life Sciences’ most recent funding round. This new round, which comes after having raised more than $100 million in past funding, is set to be the last opportunity for investors to participate before the company’s IPO. Labeled…

Kevin O’Leary: ‘Psychedelics Are My Highest Return This Year’

Oct 23 • 2 min read

“Out of all the sectors I’ve invested in, in this last year, that’s my highest return,” said Kevin O’Leary in a recent interview about his investments in two psychedelics companies that have gone public this year. O’Leary was speaking with Jon Najarian of football and CNBC fame on the Compound Interest podcast. The first psychedelics…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354